General Overview

We added 22 PCTs and 23 patent applications focused on psychedelics to our tracker in the month of February 2024. New entries came from the likes of Axsome Therapeutics, Empyrean Neuroscience, Tactogen, Clexio Biosciences, Gilgamesh Pharmaceuticals, and more.

(Subscribe or sign-in, below, to explore the interactive tables.)

***

First Look at Nolan Williams et al.’s Ibogaine IP: Is Co-Administration of Magnesium and Ibogaine Common Practice?

Last June in Denver at Psychedelic Science 2023, Stanford researcher Nolan Williams¹ shared preliminary findings from an observational study that saw ibogaine and magnesium administered to veterans with traumatic brain injuries.

The researcher’s preliminary presentation was very well received and ultimately followed up by a heavily anticipated January 2024 publication that drew a flurry of media attention (see Eagerly Anticipated Ibogaine Study Publishes). In the Nature Medicine article, the authors noted the challenges researchers (past and present) face in their endeavour to study and develop ibogaine into an FDA-approved therapy, owing largely to the drug’s cardiotoxic effects...